# A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive

Source: https://onco.cc/trials/nct06930794/  
OnCo record `nct06930794` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Vebreltinib in non-small-cell lung cancer, run by Beijing Pearl Biotechnology Limited Liability Company, now recruiting.

## Summary

A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive is a phase 3 interventional study registered as NCT06930794 by Beijing Pearl Biotechnology Limited Liability Company, with 300 participants planned, started 2025-07-07 and due to reach its primary completion in 2029-02. Interventions recorded: Vebreltinib combined with platinum-based doublet chemotherapy. and platinum-based doublet chemotherapy..

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06930794
- Phase: 3
- Setting: An Open-label, Randomized, Controlled, Multicenter Phase IIIb Clinical Study to Evaluate the Efficacy and Safety of Vebreltinib Enteric Capsule Combined With Platinum-based Doublet Chemotherapy Compared With Platinum-based Doublet Chemotherapy in Subjects With Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Not Received Previous Systemic Treatment and MET-Positive
- Sponsor: Beijing Pearl Biotechnology Limited Liability Company
- Enrolled: 300

## Sources

- ClinicalTrials.gov NCT06930794: https://clinicaltrials.gov/study/NCT06930794

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Vebreltinib](https://onco.cc/drugs/vebreltinib/)
- companies: [Beijing Pearl Biotechnology Limited Liability Company](https://onco.cc/companies/beijing-pearl-biotechnology-limited-liability-company/)

---
JSON: https://onco.cc/api/v1/entities/nct06930794.json